Kathleen D Kolstad1, Shufeng Li2, Virginia Steen3, Lorinda Chung4. 1. Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA. 2. Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA. 3. Division of Rheumatology, Georgetown University Medical Center, Washington, DC. 4. Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA; Division of Rheumatology, Department of Medicine, Palo Alto VA Health Care System, Palo Alto, CA. Electronic address: shauwei@stanford.edu.
Abstract
BACKGROUND: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). The purpose of this study was to assess long-term outcomes in patients with SSc-PAH. METHODS: Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma is a prospective registry of patients with SSc at high risk for or with incident pulmonary hypertension from right heart catheterization. Incident World Health Organization group I PAH patients were analyzed. Kaplan-Meier survival curves were generated for the overall cohort and those who died of PAH. Multivariate Cox regression models identified predictors of mortality. RESULTS: Survival in 160 patients with incident SSc-PAH at 1, 3, 5, and 8 years was 95%, 75%, 63%, and 49%, respectively. PAH accounted for 52% of all deaths. When restricted to deaths from PAH, respective survival rates were 97%, 83%, 76%, and 76%, with 93% of PAH-related deaths occurring within 4 years of diagnosis. Men (hazard ratio [HR], 3.11; 95% CI, 1.38-6.98), diffuse disease (HR, 2.12; 95% CI, 1.13-3.93), systolic pulmonary artery pressure (PAP) on ECG (HR, 1.06 95% CI, 1.01-1.11), mean PAP on right heart catheterization (HR, 1.03; 95% CI, 1.001-1.07), 6-min walk distance (HR, 0.92; 95% CI, 0.86-0.99), and diffusing capacity for carbon monoxide (HR, 0.65; 95% CI, 0.46-0.92) significantly affected survival on multivariate analysis. CONCLUSIONS: Overall survival in PHAROS was higher than other SSc-PAH cohorts. PAH accounted for more than one-half of deaths and primarily within the first few years after PAH diagnosis. Optimization of treatment for those at greatest risk of early PAH-related death is crucial.
BACKGROUND:Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc). The purpose of this study was to assess long-term outcomes in patients with SSc-PAH. METHODS:Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma is a prospective registry of patients with SSc at high risk for or with incident pulmonary hypertension from right heart catheterization. Incident World Health Organization group I PAH patients were analyzed. Kaplan-Meier survival curves were generated for the overall cohort and those who died of PAH. Multivariate Cox regression models identified predictors of mortality. RESULTS: Survival in 160 patients with incident SSc-PAH at 1, 3, 5, and 8 years was 95%, 75%, 63%, and 49%, respectively. PAH accounted for 52% of all deaths. When restricted to deaths from PAH, respective survival rates were 97%, 83%, 76%, and 76%, with 93% of PAH-related deaths occurring within 4 years of diagnosis. Men (hazard ratio [HR], 3.11; 95% CI, 1.38-6.98), diffuse disease (HR, 2.12; 95% CI, 1.13-3.93), systolic pulmonary artery pressure (PAP) on ECG (HR, 1.06 95% CI, 1.01-1.11), mean PAP on right heart catheterization (HR, 1.03; 95% CI, 1.001-1.07), 6-min walk distance (HR, 0.92; 95% CI, 0.86-0.99), and diffusing capacity for carbon monoxide (HR, 0.65; 95% CI, 0.46-0.92) significantly affected survival on multivariate analysis. CONCLUSIONS: Overall survival in PHAROS was higher than other SSc-PAH cohorts. PAH accounted for more than one-half of deaths and primarily within the first few years after PAH diagnosis. Optimization of treatment for those at greatest risk of early PAH-related death is crucial.
Authors: Matthew R Lammi; Stephen C Mathai; Lesley Ann Saketkoo; Robyn T Domsic; Christine Bojanowski; Daniel E Furst; Virginia D Steen Journal: Arthritis Rheumatol Date: 2016-03 Impact factor: 10.995
Authors: Micah R Fisher; Stephen C Mathai; Hunter C Champion; Reda E Girgis; Traci Housten-Harris; Laura Hummers; Jerry A Krishnan; Fredrick Wigley; Paul M Hassoun Journal: Arthritis Rheum Date: 2006-09
Authors: Marius M Hoeper; Harm Jan Bogaard; Robin Condliffe; Robert Frantz; Dinesh Khanna; Marcin Kurzyna; David Langleben; Alessandra Manes; Toru Satoh; Fernando Torres; Martin R Wilkins; David B Badesch Journal: J Am Coll Cardiol Date: 2013-12-24 Impact factor: 24.094
Authors: Melvyn Rubenfire; Mark D Huffman; Sangeetha Krishnan; James R Seibold; Elena Schiopu; Vallerie V McLaughlin Journal: Chest Date: 2013-10 Impact factor: 9.410
Authors: N Galiè; Lj Rubin; Mm Hoeper; P Jansa; H Al-Hiti; Gmb Meyer; E Chiossi; A Kusic-Pajic; G Simonneau Journal: Lancet Date: 2008-06-21 Impact factor: 79.321
Authors: D Mukerjee; D St George; B Coleiro; C Knight; C P Denton; J Davar; C M Black; J G Coghlan Journal: Ann Rheum Dis Date: 2003-11 Impact factor: 19.103
Authors: Kathleen Morrisroe; Wendy Stevens; Molla Huq; David Prior; Jo Sahhar; Gene-Siew Ngian; David Celermajer; Jane Zochling; Susanna Proudman; Mandana Nikpour Journal: Arthritis Res Ther Date: 2017-06-02 Impact factor: 5.156
Authors: George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee Journal: Curr Rheumatol Rep Date: 2019-12-07 Impact factor: 4.592
Authors: Paul M Hendriks; Diederik P Staal; Liza D van de Groep; Leon M van den Toorn; Prewesh P Chandoesing; Robert M Kauling; Hans-Jurgen Mager; Annemien E van den Bosch; Marco C Post; Karin A Boomars Journal: Pulm Circ Date: 2022-10-01 Impact factor: 2.886
Authors: Roham T Zamanian; David Badesch; Lorinda Chung; Robyn T Domsic; Thomas Medsger; Ashley Pinckney; Lynette Keyes-Elstein; Carla D'Aveta; Meagan Spychala; R James White; Paul M Hassoun; Fernando Torres; Andrew J Sweatt; Jerry A Molitor; Dinesh Khanna; Holden Maecker; Beverly Welch; Ellen Goldmuntz; Mark R Nicolls Journal: Am J Respir Crit Care Med Date: 2021-07-15 Impact factor: 30.528
Authors: Pailin Ratanawatkul; Joshua J Solomon; Darlene Kim; Marjorie P George; Lia R Matarrese McGibbon; M Kristen Demoruelle; Mehrnaz Maleki-Fischbach; Isabelle Amigues; Liudmila Kastsianok; Evans R Fernández Pérez Journal: ERJ Open Res Date: 2020-06-15